Skip to main content

Table 2 Trial performance

From: Design of a trial evaluating myocardial cell protection with cariporide, an inhibitor of the transmembrane sodium-hydrogen exchanger: the Guard During Ischemia Against Necrosis (GUARDIAN) trial

 

Total

UA/NSTEMI

PCI

CABG

Enrolment

    

   Projected

9 000

40-50%

20-35%

10-20%

   Actual*

11 590

45%

30%

25%

Event rate

    

   Projected

13.12%

10-15%

10-15%

20-25%

   Actual

12.95%

12.72%

10.91%

15.78%

  1. *The total number of patients recruited was readjusted followed a blinded interim analysis that showed an event rate slightly lower than expected.
Back to article page

Trials

ISSN: 1745-6215